Ernexa Therapeutics Inc.
NASDAQ: ERNA0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Sanjeev Luther
- Employees
- 6
- Headquarters
- Cambridge, United States
- IPO year
- 1991
- Market cap
- $2.0M
- Website
- https://www.ernexatx.com
Loading ERNA…
Loading profile data…Frequently asked questions about ERNA
What does Ernexa Therapeutics Inc. (ERNA) do?
Ernexa Therapeutics Inc. is a biotechnology firm currently in its preclinical development phase, specializing in the creation of therapeutic interventions using induced mesenchymal stem cells (iMSCs). The company's primary focus lies in addressing solid tumor cancers and a range of autoimmune diseases. Its flagship candidate, ERNA-101, is an all...
Where does ERNA trade?
Ernexa Therapeutics Inc. (ERNA) trades on the NASDAQ Global Market.
What sector is ERNA in?
Ernexa Therapeutics Inc. (ERNA) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Ernexa Therapeutics Inc.?
Sanjeev Luther is the chief executive officer of Ernexa Therapeutics Inc. (ERNA).
Where is Ernexa Therapeutics Inc. headquartered?
Ernexa Therapeutics Inc. is headquartered in United States.
Does ERNA pay a dividend?
Ernexa Therapeutics Inc. (ERNA) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did ERNA go public?
Ernexa Therapeutics Inc. (ERNA) completed its initial public offering in 1991.